Skip to main content
    M

    Milestone Pharmaceuticals Inc (MIST)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.41
    +0.05 (+13.21%)

    Market Cap: $45.44M

    Last updated: Nov 17, 2026 at 4:43 PM ET

    Milestone Pharmaceuticals Inc (MIST) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Milestone Pharmaceuticals (MIST) has a market cap of $45.44M. Revenue grew 4812.96% over the last 12 months from the 12 months before. It kept -1844.80% of revenue as net income over the last 12 months.

    Total Valuation

    Market Cap$45.44M
    Latest price (Nov 17, 2026)$0.41

    Key Dates

    The next earnings report is expected on Mar 18, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 18, 2027 (expected)
    Last Earnings DateNov 13, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count held steady in the quarter ended Sep 30, 2026 and grew 37.15% a year over 2 years.

    Shares Outstanding124.50M
    Shares Change (YoY)+29.02%
    Shares Change (QoQ)0.00%
    Share Count Growth (2Y CAGR)+37.15%

    Valuation Ratios

    The price to sales ratio is 9.7x. Its year-end P/S ranged from 3.5x to 109.6x from 2020 to 2025.

    P/S Ratio9.7x
    Forward P/S11.9x

    Valuation history and multiples

    Price Statistics

    The stock is down 79.34% over 52 weeks and trades 46.75% below its 50-day average.

    Beta (1Y)2.80
    52-Week Change-79.34%
    1-Month Change-40.98%
    3-Month Change-61.74%
    6-Month Change-71.10%
    5-Year Change-87.03%
    Total Return (1Y)-79.34%
    Total Return (3Y CAGR)-42.72%
    Total Return (5Y CAGR)-42.09%
    Max Drawdown (1Y)-87.63%
    Max Drawdown (3Y)-89.23%
    Sharpe Ratio (1Y)-2.03
    Correlation with SPY (1Y)0.44
    50-Day Average$0.77
    200-Day Average$1.29
    52-Week Range$0.36 to $3.06
    RSI (14 Days)29.3
    Average Volume (20 Days)2.05M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 6.27x current liabilities.

    Current Ratio6.27x
    Quick Ratio6.01x
    Interest Coverage-7.62x

    Returns and Efficiency

    Return on invested capital is -133.93% over the last 12 months, against a 5-year average of -49.35%.

    Return on Assets (ROA)-60.16%
    Return on Invested Capital (ROIC)-133.93%
    Return on Capital Employed (ROCE)-66.90%
    ROA (5Y Average)-60.80%
    ROIC (5Y Average)-49.35%
    Asset Turnover0.04x
    Inventory Turnover0.07x
    Receivables Turnover1.35x
    Cash Conversion Cycle-2823 days

    Scores

    MIST has an Altman Z-Score of -5.04, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-5.04
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $5.31M over the last 12 months.

    Revenue$5.31M
    Revenue Growth (YoY)+4812.96%
    Gross Profit$4.93M
    Operating Income-$91.60M
    Pretax Income-$97.89M
    Net Income-$97.89M
    EBITDA-$90.93M
    EBIT-$91.60M
    Reported EPS (TTM)-$0.74

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$144.47M
    Total Debt$60.25M
    Net Cash$84.22M
    Net Cash Per Share$0.68
    Working Capital$135.82M
    Shareholder Equity-$6.22M
    Total Assets$162.69M
    Total Liabilities$168.91M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $358.00K of capital spending, operating cash flow left -$77.14M of free cash flow.

    Operating Cash Flow-$76.78M
    Capital Expenditures$358.00K
    Free Cash Flow-$77.14M
    FCF Per Share-$0.62
    Depreciation and Amortization$673.00K

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -1726.39%.

    Gross Margin93.01%
    Operating Margin-1726.39%
    Pretax Margin-1844.80%
    Net Margin-1844.80%
    EBITDA Margin-1713.70%
    EBIT Margin-1726.39%
    FCF Margin-1453.86%

    Growth

    Revenue fell 32.38% a year over 3 years.

    Revenue Growth (3Y CAGR)-32.38%
    Book Value Per Share Growth (2Y CAGR)-0.29%
    Tangible Book Per Share Growth (2Y CAGR)-0.29%

    Revenue and profit by year

    Dividends and Yields

    MIST does not pay a dividend. Its free cash flow yield is -149.96%.

    FCF Yield-149.96%
    Buyback Yield-49.62%
    Shareholder Yield-49.62%

    Peer Position

    Against 5 similar companies, MIST has the 5th highest P/S.

    P/S Ratio9.7x vs 16.9x median
    Revenue Growth (Trailing 4 Quarters, YoY)+4812.96% vs -100.00% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 256.14% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+256.14%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About MIST

    What is MIST's market cap?

    Milestone Pharmaceuticals has a market cap of $45.44M.

    How many shares of MIST are outstanding?

    Milestone Pharmaceuticals has 124.50M shares outstanding. The count is up 29.02% from a year earlier.

    Does MIST pay a dividend?

    No. Milestone Pharmaceuticals does not pay a dividend.

    How much debt does MIST have?

    Milestone Pharmaceuticals has $60.25M of total debt and $144.47M of cash and equivalents, a net cash position of $84.22M.